Gliquidone

Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).

Gliquidone
Clinical data
Trade namesGlurenorm
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • C
Routes of
administration
Oral (tablets)
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityHigh (Tmax = 2–3 hours)
MetabolismExtensive hepatic
Onset of action1–1.5 hours
ExcretionBiliary (95%), renal (5%)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.046.770
Chemical and physical data
FormulaC27H33N3O6S
Molar mass527.64 g·mol−1
3D model (JSmol)
  (verify)

Contraindications

Pharmacokinetics

Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients suffering from kidney disease and diabetic nephropathy.[1]

References

  1. "Glurenorm (gliquidone) 30 mg Tablets, for Oral Use. Full Prescribing Information". Russian State Register of Medicinal Products (in Russian). Boehringer Ingelheim. Archived from the original on 14 August 2016. Retrieved 12 July 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.